The following corrections for the above-referenced paper both clarify and correct problems identified with presentation and legends for some of the figures. Immunoblotting with anti-TGF-B1 on ECM protein fraction during stages of the implantation period (n ¼ 3 per stage) exhibited latent TGF-B1. B) LAP was investigated in the uterine ECM fraction as well, where it formed a complex with latent TGF-B1. C) LTBP-1 was also analyzed to see its association with latent TGF-B1. Protein-loading control b-actin is shown in A, B, and C. Collagen a1 Type I was used as an ECM compartment marker (A-C). In all cases, because of limited material, experimental replicates were run on separate gels. Thus, the lanes illustrated in the composite blots of A, B, and C represent different developmental stages assembled as vertical slices from separate blots (run at different times), a fact denoted by white lines between lanes. For better visualization, actin controls for A, B, and C were run under denaturing conditions (in contrast to the nondenaturing condition of the experimental gels). Therefore, they were run at a separate time and do not, in the strictest sense, represent a true control. The images in the actin panels were formed from vertical slices of respective representative lanes from separate gels. A similar process of vertical slicing from separate gels run under different conditions at different times was used to assemble the collagen images in A, B, and C, and these, too, are not controls in the strictest sense. 
The following corrections for the above-referenced paper both clarify and correct problems identified with presentation and legends for some of the figures. Figure 1 Legend: The legend did not fully describe all gels and the process by which each was attained. Text has been added.
FIG. 1. Evaluation of latent TGF-B1 expression in the uterine ECM during the implantation period. A)
Immunoblotting with anti-TGF-B1 on ECM protein fraction during stages of the implantation period (n ¼ 3 per stage) exhibited latent TGF-B1. B) LAP was investigated in the uterine ECM fraction as well, where it formed a complex with latent TGF-B1. C) LTBP-1 was also analyzed to see its association with latent TGF-B1. Protein-loading control b-actin is shown in A, B, and C. Collagen a1 Type I was used as an ECM compartment marker (A-C). In all cases, because of limited material, experimental replicates were run on separate gels. Thus, the lanes illustrated in the composite blots of A, B, and C represent different developmental stages assembled as vertical slices from separate blots (run at different times), a fact denoted by white lines between lanes. For better visualization, actin controls for A, B, and C were run under denaturing conditions (in contrast to the nondenaturing condition of the experimental gels). Therefore, they were run at a separate time and do not, in the strictest sense, represent a true control. The images in the actin panels were formed from vertical slices of respective representative lanes from separate gels. A similar process of vertical slicing from separate gels run under different conditions at different times was used to assemble the collagen images in A, B, and C, and these, too, are not controls in the strictest sense. 
MATERIALS AND METHODS

Reagents
Normal rabbit IgG (sc-2027) and active human TGF-B1 protein (ab50036) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and Abcam (Cambridge, MA) respectively.
RESULTS
TGF-B1-LAP-LTBP-1 Interaction Confirmation Study
To verify that anti-TGF-B1 and LAP recognized LLC and SLC, we performed an IP study on the uterine crude plasma membranous protein extract from each studied implantation stage. The TGF-B1 IP blot was probed with anti-LTBP-1, which showed the presence of LTBP-1 in all the stages of implantation studied (Fig. 4A) . Further, we performed immunoblotting with anti-LAP on the TGF-B1 IP blot, and LAP was seen in all the stages studied (Fig. 4B) , which strengthens our finding that the LTBP-1 and LAP associate in the TGF-B1 latent complex in the uterus during embryo implantation.
On the blot probed with anti-TGF-B1, the protein band size of ;13 kDa (monomer) of mature/active TGF-B1 in the IP sample is slightly higher than the expected size as seen in recombinant human TGF-B1 monomer (Fig. 4C) . Similarly, the homodimer of mature TGF-B1 (;25 kDa) in the IP samples appeared lower than the recombinant human TGF-B1 protein (Fig. 4C) . This phenomenon could be due to some posttranslation modification (glycosylation) or salting of TGF-B1 in the mouse uterine tissue IP samples along with reducing SDS-PAGE condition. Further, when a blot was probed with only goat HRP-conjugated anti-rabbit IgG, protein bands of more than ;27 kDa along with ;50 kDa (IgG heavy chain) appeared (Fig. 4D ), but no protein bands of ;13-and/or 25-kDa size as in the anti-TGF-B1 antibody (Fig. 4C) on blots of Day 4 (1000 h) IP and normal rabbit IgG samples under denatured condition, suggesting some nonspecific binding and perhaps indicating contamination of heavy and light chains of IgG, which normally occurs in the IP samples. The TGF-B1 antibody recognized ;25-and ;13-kDa protein bands on the blot of TGF-B1 IP samples (Fig. 4C ), but these bands were not seen on the blots of Day 4 (1000 h) TGF-B1 IP, recombinant human TGF-B1 protein, or normal rabbit IgG samples (reducing conditions) when probed with secondary antibody alone (without primary antibody) (Fig. 4D) , which indicates that the ;25-and ;13-kDa protein bands are anti-TGF-B1-specific TGF-B1 homodimer and monomer respectively. A and B) For LTBP-1 and LAP immunoblots, the TGF-B1 IP samples were separated on a single reducing 10% SDS-PAGE, transferred on PVDF membrane, and immunoblotted using anti-LTBP-1 and LAP antibodies on separate blots run at different times. C) The TGF-B1 immunoblot was prepared from a separate single 12% SDS-PAGE (under reducing conditions) blotted on PVDF membrane. Detection of the anti-TGF-B1 antibody showed ;13 kDa (monomer) and ;25 kDa (homodimer) protein bands near the region of recombinant human TGF-B1 protein (;12 and ;25 kDa). D) Specificity of primary and secondary antibodies was confirmed by probing a separate blot with only goat anti-rabbit IgG HRP. This blot displays samples of Day 4 (1000 h) TGF-B1 IP, recombinant human TGF-B1 protein (20 lg/lane) and normal rabbit IgG, run under reducing conditions. When probed with goat HRP-conjugated anti-rabbit IgG, this blot showed protein bands of more than ;27 kDa along with ;50 kDa (IgG heavy chain), but no protein bands of ;13-and/or 25-kDa size (as specifically recognized by TGF-B1 antibody; C).
